PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGadoterate meglumine
Gadoterate meglumine
Clariscan, Dotarem, Gadoterate Meglumine (gadoterate meglumine) is a small molecule pharmaceutical. Gadoterate meglumine was first approved as Dotarem on 2013-03-20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Clariscan, Dotarem, Gadoterate meglumine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadoterate meglumine
Tradename
Company
Number
Date
Products
DOTAREMGuerbetN-204781 RX2013-03-20
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
clariscanANDA2024-09-17
dotaremNew Drug Application2025-03-14
gadoterate meglumineANDA2025-04-16
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V08: Contrast media
V08C: Magnetic resonance imaging contrast media
V08CA: Paramagnetic contrast media
V08CA02: Gadoteric acid
HCPCS
Code
Description
A9575
Injection, gadoterate meglumine, 0.1 ml
Clinical
Clinical Trials
50 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N181112
Heart failureD006333EFO_0003144I50112
Hip fracturesD006620EFO_0003964S72.00112
Local anesthesiaD000772112
Postoperative painD010149G89.1811
Lung diseasesD008171EFO_0003818J98.411
Interstitial lung diseasesD017563EFO_0004244J84.911
FibrosisD00535511
Pulmonary fibrosisD011658J84.1011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CardiomyopathiesD009202EFO_0000318I4222
Takotsubo cardiomyopathyD054549EFO_1002000I51.8111
Male breast neoplasmsD01856711
Autoimmune diseasesD001327EFO_0000540M30-M3611
NeoplasmsD009369C8011
Myocardial perfusion imagingD05541411
Brain diseasesD001927G93.4011
HypertensionD006973EFO_0000537I1011
SepsisD018805EFO_0001420A41.911
Acute kidney injuryD058186N1711
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGadoterate meglumine
INN
Description
Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.
Classification
Small molecule
Drug classgadolinium derivatives (principally for diagnostic use)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID72573-82-1
RxCUI
ChEMBL IDCHEMBL2219415
ChEBI ID73727
PubChem CID158536
DrugBankDB09132
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,800 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clariscan, Dotarem, Gadoterate meglumine
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,149 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use